144 results about "Stromal cell" patented technology

The invention discloses a bionic bone marrow microenvironment assembly for hematopoietic stem cell in-vitro amplification and a preparation method. The bone marrow microenvironment assembly comprises a three-dimensional scaffold and osteoblasts (OBs), wherein the three-dimensional scaffold comprises chitosan (CS) and sodium alginate (Alg) which are prepared into mixed gel, and the mixed gel is freeze-dried to prepare the three-dimensional scaffold; wherein the osteoblasts (OBs) are obtained by culturing and induced differentiation of umbilical cord mesenchymal stem cells (MSCs) inoculated on a three-dimensional scaffold, and the osteoblasts (OBs) as stromal cells and the three-dimensional scaffold jointly form the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly; in the hematopoietic stem cell in-vitro amplification bionic bone marrow microenvironment assembly, the preparation of the three-dimensional scaffold comprises the processes of freezing, remelting, freezing, crosslinking, freeze-drying and the like, so that a three-dimensional space form with wrinkles on the pore surface and pore size distribution between 70 microns and 400 microns is generated in the three-dimensional scaffold, and the three-dimensional space form is closer to a real stem cell niche; therefore, the practical application effect of the bionic bone marrow microenvironment assembly for in-vitro amplification of the hematopoietic stem cells is further improved.

The present invention provides a method of producing a population of mesenchymal stromal cells (MSC) of CD73 + CD44 +, CD90 +. The CD73 + CD44 +, CD90 + MSC is used in a method for producing terminally differentiated osteoblasts, adipoblasts and chondroblasts from pluripotent stem cells (PSCs). The differentiation methods include the use of a single agent-a WNT signaling pathway activator used on an adherent culture of PSC, such as a GSK3 [beta] inhibitor.

The present invention relates to CD73 + CD44 + , CD90 + A method for generating a population of mesenchymal stromal cells (MSCs) is provided. + CD44 + , CD90 + MSCs are used in methods to generate terminally differentiated osteogenic, adipogenic, and chondrogenic cells from pluripotent stem cells (PSCs), which involve the use of a single agent, a WNT signaling pathway activator (e.g., a GSK3β inhibitor), in adherent cultures of PSCs.

It was discovered that by binding to CTCF which is important for maintaining chromosomal structures, hSATII RNA inhibits the function thereof, changes chromosome interaction, and induces transcription of inflammation-associated genes. It has also been discovered that cell death can be selectively induced in senescent cells and cancer cells by suppressing hSATII RNA expression. From the obtained results, it has been found that cancer treatment which targets senescent stromal cells and cancer cells can be performed with a substance that suppresses hSATII RNA or a substance that increases CTCF expression. In addition, cancer can be detected early by measuring the expression and activity of hSATII RNA and CTCF, and an epigenomic change of the hSATII DNA region. Thus, it is possible to provide a therapeutic drug for a cancer associated with cellular senescence, a method for screening thereof, and a test support method.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

This invention belongs to the field of biomedical technology, specifically relating to a rapid purification method for umbilical cord MSC exosomes and their application in the preparation of drugs for treating COPD. This invention discloses a method for rapidly purifying umbilical cord mesenchymal stromal cell (MSC) exosomes and a pharmaceutical composition comprising umbilical cord MSC exosomes and yamosaponin. In this pharmaceutical composition, the umbilical cord MSC exosomes and yamosaponin synergistically enhance the dynamic compliance of COPD rats, reduce airway resistance, decrease pulmonary inflammation, and repair pulmonary dysfunction. This invention provides a new technical solution for the preparation of drugs for treating or improving COPD.

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The present invention relates to the use of mesenchymal stem cells (MSCs) for enhancing the immune response of elderly or animal subjects to vaccination. According to the application, the defects of spleen stromal cell networks and lymphocyte structures of old subjects can be repaired by applying the MSC in advance, and the immune level of organisms is improved; and the vaccine is injected after a period of time, so that the specific antibody level after vaccine immunization can be improved. The effect can also significantly prevent the elderly subjects from being infected by influenza. Therefore, the MSC has a good application prospect in solving related immune decline of old people.

This invention belongs to the field of biomedical technology, specifically relating to the application of mesenchymal stem cells in the preparation of anti-aging drugs. The mesenchymal stem cells are human adipose-derived mesenchymal stem cells (hAMSCs) or mouse bone marrow mesenchymal stem cells (BM-MSCs). This invention utilizes mesenchymal stem cells to regulate senescent stromal cells and the spleen's ECM, improving the thinning stromal state in the tissue microenvironment through multiple targets. Specifically, it improves the aging-related secretory phenotype of stromal cells, enhances mitochondrial activity, strengthens their proliferation capacity, and delays the reduction of collagen secretion. This, in turn, delays the disordered distribution and functional decline of immune cells caused by aging and enhances tissue regeneration capacity, indirectly affecting various other cells in the tissue microenvironment, thus exhibiting an antagonistic effect against systemic organ aging.

The invention discloses an application of a JAM3 modified engineered vesicle in preparation of a medicine for treating bone injury, the JAM3 modified engineered vesicle is prepared, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on bone marrow mesenchymal stem cells (BMSCs) is proved through ALP staining, RT-qPCR, WB and other experiments at the cellular level, so that the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved, and the osteogenesis promoting effect of the JAM3 modified engineered vesicle on the bone marrow mesenchymal stem cells (BMSCs) is improved. Meanwhile, the effect of JAM3 modified engineered vesicles on promoting osteogenesis of bone defect mice is defined through in-vivo experiments. According to the invention, osteogenesis direction differentiation and bone formation capability of BMSC can be promoted, and bone formation capability of bone defect mice can be promoted in vivo; the compound can be used for treating related diseases such as bone injury.

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and / or decreasing the amount of TGFβR2, and / or decreasing the amount of and / or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells (hCT-MSCs) to treat Autism Spectrum Disorder. The methods involve treating a patient having or suspected of having an Autism Spectrum Disorder by administering a therapeutically effective amount of hCT-MSCs.

The present application relates to the technical field of biological medicine, and more particularly to a culture solution, a kit and an application for in-vitro maturation of aged oocytes. Through in-vitro experiments, the present application adds exogenous stromal cell-derived factor 1, establishes a culture system for in-vitro maturation of aged oocytes, and reveals the molecular mechanism of stromal cell-derived factor 1 playing a role through autophagy, thereby providing a new solution for improving the fertility of aged women and improving the success rate of assisted reproductive technology, and having important clinical application value.

The present disclosure relates to allogeneic populations of mesenchymal stem / stromal cells and related compositions, which populations and compositions comprise cells pooled from multiple donors, and their use in therapy and / or prevention of inflammatory, autoimmune, transplant related and CNS disorders, in particular CNS such as Amyotrophic Lateral Sclerosis. The present disclosure also relates to methods for obtaining said compositions.

The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.

Described herein are hydrogel compositions comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.Additionally described herein are compositions for treatment, and methods for treatment of a disease, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, hydroxypropyl methyl cellulose and a plurality of mesenchymal stromal cells.

The invention discloses a patient-specific bile duct cancer chip and a method thereof in dynamic drug resistance evolution analysis, and relates to the technical field of biomedicine, the patient-specific bile duct cancer chip comprises a central tumor microenvironment chamber, the central tumor microenvironment chamber is internally provided with a plurality of independent three-dimensional culture chambers, and patient-derived cells are embedded and loaded in a matrix; the perfusion channel network is connected with the plurality of three-dimensional culture chambers to form a flow channel and is used for continuously perfusing a culture medium, a medicine or a stromal cell suspension and simulating blood flow and interstitial fluid flow, and the microenvironment regulation and control unit is integrated with the perfusion channel network to control the flow channel. The chip provided by the invention integrates tumor cells, cancer-related fibroblasts and endothelial cells, so that the tumor cells, the cancer-related fibroblasts and the endothelial cells grow in a 3D matrix to form organoids with spatial structures and interstitial infiltration, and the microfluidic perfusion simulates blood / interstitial fluid flow, so that the drug test environment is closer to the actual situation of a human body, and the obtained data has higher physiological prediction value.

The invention discloses an application of a tumor targeting NNMT inhibitor in preparation of a drug-resistant tumor resistant drug. The NNMT inhibitor comprises an NNMT inhibitor dipeptide and a physiologically acceptable salt of the NNMT inhibitor dipeptide. The NNMT inhibitor can target tumor microenvironment FAP < + > / NNMT < + > extravascular stromal cells, reduce the expression of drug resistance promoting factors, induce blood vessel normalization, improve the infiltration of killer T cells, block the formation of tumor immunosuppression microenvironment, and enhance the curative effects of tumor immunotherapy and anti-angiogenesis therapy. The NNMT inhibitor has a remarkable immunotherapy or anti-angiogenesis treatment sensitization effect on colorectal cancer, pancreatic cancer, breast cancer, lung cancer, liver cancer, stomach cancer, prostatic cancer, ovarian cancer, melanoma and the like, and has a good application prospect in the aspect of preparing anti-drug-resistant tumor drugs.

The invention provides a method of producing a population of CD73+ CD44+, CD90+ mesenchymal stromal cells (MSCs). The CD73+ CD44+, CD90+ MSCs are used in methods of generating terminally differentiated osteogenic, adipogenic and chondrogenic cells from pluripotent stem cells (PSCs). The differentiation method includes the use of a single agent, WNT signaling pathway activator such as a GSK3β inhibitor, used on adherent culture of PSCs.

The invention relates to the field of dermatology and cosmetology and can be used for regenerating wounds and preventing and correcting age-related skin changes, as well as for stimulating hair growth. The proposed composition contains as active ingredient the secretome of mesenchymal stromal cells (MSCs) derived from mammalian adipose tissue, the secretome being provided in an amount of 50-70 ‎μg / ml and being characterized by the presence of the following secretion products: FGF-2, KGF, TGF-β, PDGF, TGF-α, IGF-1, EGF, HGF, VEGF, G-CSF, GM-CSF, PGE2, ANG-1, ANG-2, MCP-1, MMPs, cysteine, tyrosine, arginine, glycine, histidine, isoleucine, lysine hydrochloride, methionine, phenylalanine, serine, threonine, tryptophan and valine. Also proposed is a method for producing the claimed composition, which includes techniques and conditions for harvesting and cultivating MSCs, making it possible to obtain a secretome having constituents effective for the treatment and regeneration of skin and hair.

The invention belongs to the technical field of biological medicines, and particularly relates to application of emipril in preparation of a medicine for improving choroidal neovascularization related diseases. The invention aims to solve the problems of strong invasiveness and limited curative effect of the existing therapy. It is found that emipril can achieve differential regulation and control on a CD26 system in vivo, that is, the enzyme activity of CD26 in bone marrow is improved, the enzyme activity of CD26 in peripheral blood is reduced, the concentration gradient of stromal cell-derived factor-1 can be established between the bone marrow and the peripheral blood through differential regulation and control, and the concentration gradient of the stromal cell-derived factor-1 can be further improved. The bone marrow-derived cells are driven to homing to eye lesions and differentiate into repair cells, so that eye diseases are repaired or improved, meanwhile, the collection and migration of bone marrow-derived macrophages to CNV regions can be increased, and the anti-inflammatory effect is achieved. According to the application, an endogenous repair mechanism is activated through non-invasive administration, and a safer and more effective treatment method is provided for related eye diseases.

The invention relates to a preparation method and application of vitronectin, stromal cell-derived factor-1 or fusion protein hydrogel thereof, vitronectin and stromal cell-derived factor-1 are connected through a flexible joint composed of a plurality of amino acids to form a fusion protein, and the fusion protein can carry a purification label or does not carry a purification label; the fusion protein is finally designed into hydrogel in a self-assembly or biochemical or bio-physicochemical cross-linking mode. The hydrogel disclosed by the invention has good biocompatibility, has a remarkable effect on recruiting stem cells, can realize dryness maintenance of in-situ stem cells, can be applied to the fields of skin tissue wound healing, cartilage repair, osteoarthritis clinical treatment, bone defect repair and the like, and has important significance on wound healing and body injury repair and regeneration.

An ECM-embedded vascular channel-on-a-chip includes an outer case having an internal chamber, an ECM provided within the chamber, the ECM having a cross-sectionally rounded vascular channel having a first end and a second end opposite the first end, wherein an immer surface of the channel is lined with barrier-forming endothelial cells, and an inlet conduit coupled to the first end of the channel through a first side of the outer casc and an outlet conduit coupled to the second end of the channel through a second side of the outer case. Also, an airway-on-a-chip includes an airway lumen including a porous membrane, wherein mucociliated airway epithelial cells are provided on the porous membrane. The airway-on-a-chip has an ECM with embedded stromal cells. The ECM has a cross-sectionally rounded vascular channel, and the inner surface of the channel is lined with barrier-forming endothelial cells.

Compositions and methods including stromal cells that have been genetically engineered to knock down or silence one or more genes are disclosed herein. The compositions include a population of isolated stromal cells that have been genetically engineered to reduce or eliminate expression one or more genes which confers permissivity to invasion (referred to herein as INVGOI) in fibroblasts, or cancer associated fibroblasts (CAFs). The cell compositions can be administered to a subject in need thereof to reduce or eliminate expression of one or more genes which confer permissivity to cancer invasion. Alternatively, inhibitory functional nucleic acids which specifically target one or more INV-GOI can be administered to a subject to treat cancer and in additional to chemotherapy, to sensitize cancer cells to chemotherapy.

Provided herein are methods of using mesenchymal stromal / stem cell (MCS) exosomes in the treatment of diseases associated with thymic dysfunction. In some embodiments, the MSC exosomes restore thymic architecture and development in a subject having thymic dysfunction (e.g., caused by exposure to hyperoxia). In some embodiments, the subject is a human subject (e.g., a human neonate).

The utility model discloses a device suitable for fat stromal cell extraction, which comprises a bag body, the bag body internally comprises at least a first accommodating cavity and a second accommodating cavity, the first accommodating cavity is used for filling cleaning fluid, and the second accommodating cavity is used for filling digestive juice; the liquid inlet pipe is connected with one side of the accommodating cavity I; the waste liquid pipe is connected with one side of the accommodating cavity I; the liquid outlet pipe is connected with one side of the first containing cavity. According to the device, the fat matrix can be directly cleaned and digested in the same device suitable for extracting the fat matrix cells, an operator does not need to add cleaning liquid and digestion liquid, operation steps are reduced, and cross contamination can be effectively avoided.

The invention relates to methods for extracting, purifying and concentrating mesenchymal stromal cell exosomes enriched with micro-RNA, proteins and lipids, and can be used in cosmetology and pharmacology for rehabilitation and regeneration. The technical result of the invention is a more efficient process for producing exosomes. This technical result is achieved in that the present method for extracting, purifying and concentrating exosomes from mesenchymal stromal cells includes cultivating cells, collecting the conditioned culture medium, depleting high-molecular-weight proteins, extracting, purifying and concentrating exosomes, and freezing and lyophilizing the exosome concentrate; in order to enrich the culture medium with exosomes, multipotent mesenchymal stem cells (MSCs) are grown in a medium having a lowered glucose concentration and containing platelet lysate and 5 mM of L-alanyl-L-glutamine, wherein, in the case of static cell cultivation, the growth medium is placed in a culture vessel and once a level of not less than 80% monolayer confluence is reached, the culture medium is harvested and replaced once every 24 hours, and in the case of flow-through cell cultivation, cells are placed on cell carriers in a bioreactor and 72-96 hours after the start of cultivation, the culture medium is harvested and replaced once every 24 hours, the exosome-enriched culture medium is subjected to concentration, which includes successive stages of centrifugation, tangential flow filtration and isopycnic centrifugation: in the first stage, the culture medium is centrifuged for 10 mins at 2000 g to remove large cell particles and other inclusions; in the tangential flow filtration stage, the supernatant is concentrated using hollow fibre filters having a molecular weight cutoff of 500 kDa, after which the concentrate is subjected to fivefold diafiltration with an equal volume of DPBS phosphate buffer solution using the same hollow fibre cartridge; and in the isopycnic centrifugation stage, the concentrated supernatant is mixed with a saccharose solution and deuterium oxide and subjected to isopycnic centrifugation at 100000 g and 4˚С for 75 mins, after which the concentrate is subjected to further fivefold diafiltration with a buffer solution, then the concentrate is filtered through filters with a pore diameter of 0.22 µm and 0.1 µm, the exosome concentrate is subjected to initial freezing to -75˚C in a freezing chamber, and drying is carried out in a lyophilization chamber, wherein in a first drying stage, the concentrate is cooled to -40˚С and subsequently held for 100 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -30˚С and subsequently held for 610 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -10˚С and subsequently held for 315 mins at an absolute pressure in the chamber of not more than 10 Pa, after which it is cooled to 0˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa, then heated to +10˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa; in a second drying stage, drying is carried out at +22˚С for not less than 130 minutes at an absolute pressure in the chamber of not more than 10 Pa.

A method for testing an anticancer effect including culturing a cell structure including cancer cells and stromal cells in a presence of an anticancer drug and immune cells, and measuring the number of living cancer cells in the cell structure after the culturing, as an indicator of an anticancer effect of the anticancer drug or the immune cells.